Antifungal drug susceptibility testing and resistance in Aspergillus

Drug Resistance Updates

Volumn 2, Issue 5, 1999, Pages 326-334

  Warnock, David W ^a   Arthington Skaggs, Beth A ^a   Li, Ren Kai ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CAPSOFUNGIN; CASPOFUNGIN; CILOFUNGIN; ECHINOCANDIN B DERIVATIVE; ITRACONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STANDARDIZATION;

EID: 0033208399     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0092     Document Type: Article

References (96)

1. Nolard N., Detandt M., Beguin H. Ecology of Aspergillus species in the human environment. Vanden Bossche H., Mackenzie D. W. R., Cauwenbergh G., Aspergillus and Aspergillosis. 1988;35-41 Plenum Press, New York.
2. Denning D. W. Invasive aspergillosis. Clin Infect Dis. 26:1998;781-805.
3. Denning D. W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 23:1996;608-615.
4. Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microb Physiol. 27:1986;1-72.
5. Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 34:1990;183-188.
6. Vanden Bossche H. Biochemical targets for azole antifungal derivatives: hypothesis on the mode of action. McGinnis M., Current Topics in Medical Mycology. 1985;313-351 Springer-Verlag, New York.
7. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical use. Rev Infect Dis. 12:1990;308-329.
8. Wong-Beringer A., Jacobs R. A., Guglielmo B. J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 27:1998;603-618.
9. Hamilton-Miller J. M. T. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev. 37:1973;166-196.
10. Mehta R. T., Hopfer R. L., Gunner L. A., Juliano R. L., Lopez-Berestein G. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother. 31:1987;1897-1900.
11. Johnson E. M., Ojwang J. O., Szekely A., Wallace T. L., Warnock D. W. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 42:1998;1412-1416.
12. Wallace T. L., Paetznick V., Cossum P. A., Lopez-Berestein G., Rex J. H., Anaissie E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother. 41:1997;2238-2243.
13. Groll A. H., Gonzalez C. E., Giri N. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J Antimicrob Chemother. 43:1999;95-103.
14. Boutati E., Maltezou H. C., Lopez-Berestein G., Vartivarian S. E., Anaissie E. Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with hematological malignancies. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995;American Society for Microbiology, Washington, DC. p. abstract LM22
15. Denning D. W., Lee J. Y., Hostelter J. S. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 97:1994;135-144.
16. Prentice A. G., Warnock D. W., Johnson S. A. N., Phillips M. J., Oliver D. A. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother. 34:1994;247-252.
17. Murphy M., Bernard E. M., Ishimaru T., Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 41:1997;696-698.
18. Clancy C. J., Nguyen M. H. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis. 17:1998;573-575.
19. Cuenca-Estrella M., Rodriguez-Tudela J. L., Mellado E., Martinez-Suarez J. V., Monzon A. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother. 42:1998;531-533.
20. Johnson E. M., Szekely A., Warnock D. W. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 42:1998;741-745.
21. Oakley K. L., Moore C. B., Denning D. W. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother. 42:1998;91-94.
22. Verweij P. E., Mensink M., Rijs A. J. M. M., Donnelly J. P., Meis J. F. G. M., Denning D. W. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmentalAspergillus fumigatus isolates. J Antimicrob Chemother. 42:1998;389-392.
23. George D., Miniter P., Andriole V. T. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 40:1996;86-91.
24. Martin M. V., Yates J., Hitchcock C. A. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother. 41:1997;13-16.
25. Denning D. W., del Favero A., Gluckman E. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995;American Society for Microbiology, Washington, DC. p. abstract F80.
26. Dupont B., Denning D., Lode H., Sarantis N., Troke P. F., Yonren S. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995;American Society for Microbiology, Washington, DC. p. abstract F81.
27. Dupont B., Improvisi L., Dromer F. In vitro and in vivo activity of a new antifungal agent SCH56592 (SCH). Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996;American Society for Microbiology, Washington, DC. p. abstract F93.
28. Fothergill A. W., Sutton D. A., Rinaldi M. G. An in vitro head-to-head comparison of Schering 56592, amphotericin B, fluconazole, and itraconazole against a spectrum of filamentous fungi. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996;American Society for Microbiology, Washington, DC. p. abstract F89.
29. Oakley K. L., Moore C. B., Denning D. W. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole againstAspergillus spp. Antimicrob Agents Chemother. 41:1997;1124-1126.
30. Cacciapuoti A., Parmegiani R., Loebenberg D. Efficacy of SCH 56592 in pulmonary aspergillosis and candidiasis in mice. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995;American Society for Microbiology, Washington, DC. p. abstract F66.
31. Graybill J. R., Bocanegra R., Najvar L. K., Luther M. F., Loebenberg D. SCH 56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother. 42:1998;539-542.
32. Oakley K. L., Morrissey G., Denning D. W. Efficacy of SCH 56592 in two immunocompromised murine models of invasive aspergillosis. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996;American Society for Microbiology, Washington, DC. p. abstract F97.
33. Patterson T. F., Kirkpatrick W. R., McAtee R. K., Loebenberg D. Efficacy of SCH 56592 in a rabbit model of invasive aspergillosis. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996;American Society for Microbiology, Washington, DC. p. abstract F98.
34. Debono M., Gordee R. S. Antibiotics that inhibit fungal cell wall development. Ann Rev Microbiol. 48:1994;471-497.
35. Pfaller M. A., Gerarden T., Yu M., Wenzel R. P. Influence of in vitro susceptibility testing conditions on the anticandidal activity of LY121019. Diagn Microbiol Infect Dis. 11:1989;1-9.
36. Huang A., Edwards F., Bernard E. M., Armstrong D., Schmitt H. J. In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus andCandida species. Eur J Clin Microbiol Infect Dis. 9:1990;697-699.
37. Denning D. W., Stevens D. A. Efficacy of ciolfungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 35:1991;1329-1333.
38. Beaulieu D., Tang J., Zeckner D. J., Parr T. R. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase. FEMS Microbiol Lett. 108:1993;133-137.
39. Zhanel G. G., Karlowsky J. A., Harding G. A. J. In vitro activity of a new semisynthetic echinocandin, LY 303366, against systemic isolates of Candida species,Cryptococcus neoformans , Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 41:1997;863-865.
40. Oakley K. L., Moore C. B., Denning D. W. In vitro activity of the echinocandin antifungal agent LY 303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother. 42:1998;2726-2730.
41. Pfaller M. A., Marco F., Messer S. A., Jones R. N. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743872), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 30:1998;251-255.
42. Zeckner D., Butler T., Boylan C. LY303366 activity against systemic aspergillosis and histoplasmosis in murine models. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 1993;American Society for Microbiology, Washington, DC. p. abstract 364.
43. Raab P., Zeckner D., Boyll B., Boylan C., Current W. LY303366: comparison of activity in murine models of Aspergillus fumigatus infection. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1994;American Society for Microbiology, Washington, DC. p. abstract F167.
44. Verweij P. E., Oakley K. L., Morrissey J., Morrisset G., Denning D. W. Efficacy of LY 303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother. 42:1998;873-878.
45. Bartizal K., Gill C. J., Abruzzo G. K. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743872). Antimicrob Agents Chemother. 41:1997;2326-2332.
46. Espinel-Ingroff A. In vitro studies with L-743,872, a water soluble pneumocandin: a comparative study. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996;abstract F31.
47. Fothergill A. W., Sutton D. A., Rinaldi M. G. Antifungal susceptibility testing of Merck L-743,872 against a broad range of fungi. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996;American Society for Microbiology, Washington, DC. p. abstract F29.
48. Abruzzo G. K., Flattery A. M., Gill C. J. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 41:1997;2333-2338.
49. Bernard E. M., Ishimaru T., Armstrong D. Low doses of the pneumocandin, L-743,872, are effective for prevention and treatment in an animal model of pulmonary aspergillosis. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996;American Society for Microbiology, Washington, DC. p. abstract F39.
50. Smith J. G., Abruzzo G. K., Gill C. J. Evaluation of pneumocandin L-743872 in neutropenic mouse models of disseminated candidiasis and aspergillosis. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996;American Society for Microbiology, Washington, DC. p. abstract F41.
51. Denning D. W., Radford S. A., Oakley K. L., Hall L., Johnson E. M., Warnock D. W. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother. 40:1997;401-414.
52. Denning D. W., Venkateswarlu K., Oakley K. L. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 41:1997;1364-1368.
53. Odds F. C. Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother. 6:1980;749-761.
54. Johnson E. M., Richardson M. D., Warnock D. W. In-vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother. 13:1984;547-558.
55. Doern G. V., Tubert T. A., Chapin K., Rinaldi M. G. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol. 24:1986;507-511.
56. Galgiani J. N., Reiser J., Brass C., Espinel-Ingroff A., Gordon M. A., Kerkering T. M. Comparison of relative susceptibility of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother. 31:1987;1343-1347.
57. Calhoun D. L., Roberts G. D., Galgiani J. N. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol. 23:1986;298-301.
58. Approved standard. Document M27-A. 1997.
59. Manavathu E. K., Cutright J., Chandrasekar P. H. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents. J Clin Microbiol. 37:1999;858-861.
60. Guarro J., Llop C., Aguilar C., Pujol I. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob Agents Chemother. 41:1997;2760-2762.
61. Pfaller M. A., Rinaldi M. G., Galgiani J. N. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother. 34:1990;1648-1654.
62. Gehrt A., Peter J., Pizzo P. A., Walsh T. J. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol. 33:1995;1302-1307.
63. Espinel-Ingroff A., Kerkering T. M. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J Clin Microbiol. 29:1991;393-394.
64. Espinel-Ingroff A., Pfaller M. A., Dawson K. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 39:1995;314-319.
65. Espinel-Ingroff A., Bartlett M. S., Bowden R. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol. 35:1997;139-143.
66. Proposed standard. Document M38-P. 1998.
67. Espinel-Ingroff A., Silvius M. A. The Etest for antifungal susceptibility testing of opportunistic filamentous fungi. Abstracts of the 96th General Meeting of the American Society for Microbiology. 1996;American Society for Microbiology, Washington DC. p. abstract C262.
68. Mills K., Wanger A. Evaluation of Etest for antifungal susceptibility testing of filamentous fungi. Abstracts of the 96th General Meeting of the American Society for Microbiology. 1996;American Society for Microbiology, Washington DC. p. abstract F66.
69. Mills K., Wanger A. Susceptibility testing of moulds using Etest. Abstracts of the 97th General Meeting of the American Society for Microbiology. 1997;American Society for Microbiology, Washington DC. p. abstract C248.
70. Szekely A., Johnson E. M., Warnock D. W. Comparison of Etest and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol. 37:1999;1480-1483.
71. Velez J. D., Allendoerfer R., Luther M., Rinaldi M. G., Graybill J. R. Correlation of in-vitro azole susceptibility with in-vivo response in a murine model of cryptococcal meningitis. J Infect Dis. 168:1993;508-510.
72. Graybill J. R., Najvar L. K., Holmberg J. D., Correa A., Luther M. F. Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response. Antimicrob Agents Chemother. 39:1995;2197-2200.
73. Rex J. H., Nelson P. W., Paetznick V. L., Lozano-Chiu M., Espinel-Ingroff A., Anaissie E. J. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother. 42:1998;129-134.
74. Rodriguez-Tudela J. L., Martinez-Suarez J. V., Dronda F., Laguna F., Chaves F., Valencia E. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J Antimicrob Chemother. 35:1995;793-804.
75. Ruhnke M., Schmidt-Westhausen A., Engelmann E., Trautmann M. Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy. J Clin Microbiol. 34:1996;3208-3211.
76. Rex J. H., Pfaller M. A., Barry A. L., Nelson P. W., Webb C. D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 39:1995;40-44.
77. Odds F. C., Van Gerven F., Espinel-Ingroff A. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother. 42:1998;282-288.
78. Lass-Florl C., Kofler G., Kropshofer G. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother. 42:1998;497-502.
79. Rath P. M. Susceptibility of aspergillus strains from culture collections to amphotericin B and itraconazole. J Antimicrob Chemother. 41:1998;567-570.
80. Oakley K. L., Morrissey G., Denning D. W. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother. 41:1997;1504-1507.
81. Sutton D. A., Sanche S. E., Revankar S. G., Fothergill A. W., Rinaldi M. G. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 37:1999;2343-2345.
82. Schaffner A., Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses. 36:1993;421-424.
83. Schafner A., Frick P. G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis. 151:1985;902-910.
84. Nucci M., Pulcheri W., Bacha P. C. Amphotericin B followed by itraconazole in the treatment of disseminated fungal infections in neutropenic patients. Mycoses. 37:1994;433-437.
85. Ziogas B. N., Sisler H. D., Lusby W. R. Sterol content and other characteristics of pimaricin-resistant mutants of Aspergillus nidulans. Pest Biochem Physiol. 20:1983;320-329.
86. Kim S. J., Kwon-Chung K. J. Polyene-resistant mutants of Aspergillus fennelliae: sterol contents and genetics. Antimicrob Agents Chemother. 6:1974;102-113.
87. Kim S. J., Kwon-Chung K. J., Milne G. W. A., Prescott B. Polyene-resistant mutants of Aspergillus fennelliae: identification of sterols. Antimicrob Agents Chemother. 6:1974;405-410.
88. Gale E. F., Johnson A. M., Kerridge D., Koh T. Y. Factors affecting the changes in amphotericin sensitivity of Candida albicans during growth. J Gen Microbiol. 87:1975;20-36.
89. Gale E. F., Johnson A. M., Kerridge D. The effect of aeration and metabolic inhibitors on resistance to amphotericin in starved cultures of Candida albicans. J Gen Microbiol. 99:1977;77-84.
90. Sokol-Anderson M. L., Sligh J. E. J., Elberg S., Brajtburg J., Kobayashi G. S., Medoff G. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother. 32:1988;702-705.
91. Manavathu E. K., Alangaden G. J., Chandrasekar P. H. In-vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus. J Antimicrob Chemother. 41:1998;615-619.
92. Capek A., Simek A., Leiner J., Weichet J. Antimycotic activity and problems of resistance. Folia Microbiologica. 15:1970;314.
93. Sanglard D., Ischer F., Calabrese D., de Micheli M., Bille J. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resistance Updates. 1:1998;255-265.
94. White T. C., Marr K. A., Bowden R. A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 11:1998;382-402.
95. deWaard M. A., van Nistelrooy J. G. M. An energy-dependent efflux mechanism for fenarimol in a wild-type strain and fenarimol-resistant mutants ofAspergillus nidulans. Pestic Biochem Physiol. 13:1980;255-266.
96. van den Brink H. J. M., van Nistelrooy J. G. M., de Waard M. A., van den Hondel C. A. M. J. J., van Gorcom R. F. M. Increased resistance to 14-alpha demethylase inhibitors (DMIs) in Aspergillus niger by coexpression of thePenicillium italicum eburicol 14-alpha demethylase (cyp51) and the A. niger cytochrome P450 reductase (cpr A) genes. J Biotech. 49:1996;13-18.